Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23714141 | 0.84 | CNR2 (0.41) | HPGD | |
| SCHEMBL8633260 | 0.78 | PREP (0.54) | PREPFFAR1HCRTR1HCRTR2 | |
| SCHEMBL5173202 | 0.73 | PREP (0.51) | PREPHPGD | |
| SCHEMBL7284818 | 0.73 | PREP (0.51) | PREPHPGD | |
| SCHEMBL11447174 | 0.73 | PREP (0.51) | PREPHPGD | |
| SCHEMBL17009656 | 0.68 | MAPT (0.57) | HPGD | |
| SCHEMBL11117347 | 0.68 | MAPT (0.60) | — | |
| SCHEMBL4400929 | 0.68 | AKR1C3 (0.57) | HPGD | |
| SCHEMBL23714138 | 0.66 | KMT2A (0.39) | PREPTP53HPGDHCRTR1HCRTR2 | |
| SCHEMBL8033801 | 0.66 | MAPT (0.72) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3100745-B1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | PREP 3423/4885FFAR1 1133/4885TP53 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.